Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP628499.RArzjokxA3j2tIzNvdkS4jqoAOuwzB4o4qtmWe4aQXMZY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP628499.RArzjokxA3j2tIzNvdkS4jqoAOuwzB4o4qtmWe4aQXMZY130_assertion type Assertion NP628499.RArzjokxA3j2tIzNvdkS4jqoAOuwzB4o4qtmWe4aQXMZY130_head.
- NP628499.RArzjokxA3j2tIzNvdkS4jqoAOuwzB4o4qtmWe4aQXMZY130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP628499.RArzjokxA3j2tIzNvdkS4jqoAOuwzB4o4qtmWe4aQXMZY130_provenance.
- NP628499.RArzjokxA3j2tIzNvdkS4jqoAOuwzB4o4qtmWe4aQXMZY130_assertion evidence source_evidence_literature NP628499.RArzjokxA3j2tIzNvdkS4jqoAOuwzB4o4qtmWe4aQXMZY130_provenance.
- NP628499.RArzjokxA3j2tIzNvdkS4jqoAOuwzB4o4qtmWe4aQXMZY130_assertion SIO_000772 22890388 NP628499.RArzjokxA3j2tIzNvdkS4jqoAOuwzB4o4qtmWe4aQXMZY130_provenance.
- NP628499.RArzjokxA3j2tIzNvdkS4jqoAOuwzB4o4qtmWe4aQXMZY130_assertion wasDerivedFrom befree-20150227 NP628499.RArzjokxA3j2tIzNvdkS4jqoAOuwzB4o4qtmWe4aQXMZY130_provenance.
- NP628499.RArzjokxA3j2tIzNvdkS4jqoAOuwzB4o4qtmWe4aQXMZY130_assertion wasGeneratedBy ECO_0000203 NP628499.RArzjokxA3j2tIzNvdkS4jqoAOuwzB4o4qtmWe4aQXMZY130_provenance.